Peripheral Neuropathy News and Research

RSS

Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.

Normalizing cholesterol metabolism in microglia alleviates chronic neuropathic pain

Chemotherapy can induce a painful peripheral neuropathy (CIPN), a chronic condition and common adverse effect for cancer patients undergoing treatment.

10 May 2021

Novel CBD analog alleviates pain in mouse model of chemotherapy-induced peripheral neuropathy

For patients with chronic pain, ineffective treatments, lowered work productivity, and other factors often coalesce, fueling feelings of hopelessness and anxiety and setting the stage for even bigger problems, including substance use disorders.

5 May 2021

FDA approves immunotherapy for first-line treatment of advanced gastric cancer

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.

16 Apr 2021

UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment

The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled "Developing a Theranostic Immunotherapy for Systemic Amyloidosis."

16 Mar 2021

An increase in the risk of clinical sequelae after SARS-CoV-2 infection

A new piece of research, published on the medRxiv preprint server, focused on the role of factors such as gender, age, hospitalization, etc., in understanding the risks of clinical sequelae in the post-acute phase of COVID-19, in adults aged between 18 and 65 years.

15 Mar 2021

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

A discovery by University of Queensland pain researchers may allow some future cancer patients, including children with leukemia, to avoid their chemotherapy's worst and most debilitating side effects.

15 Mar 2021

Study reveals potential risk factors for developing nerve damage after cancer treatment

A low hemoglobin count, older age and high BMI are possible risk factors for developing nerve damage after cancer treatment, a UNSW-led study has found.

4 Mar 2021

How SARS-CoV-2 enters the central nervous system

The central nervous system (CNS) is highly protected in the human body. Yet, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invades the CNS, causing profound clinical complications. How is the CNS involved in a respiratory virus infection?

15 Feb 2021

Unexpected neurologic complication identified in severe COVID-19

Physicians working at Cambridge University Hospital NHS Foundation Trust have reported that a significant proportion of patients with severe coronavirus disease 2019 (COVID-19) who required intensive care developed unanticipated disabling neurological deficits that were related to a mononeuritis multiplex.

29 Jul 2020

How COVID-19 affects the nervous system

A new paper published in the journal JAMA Neurology in May 2020 discusses the presentation and complications of COVID-19 with respect to the nervous system.

31 May 2020

Dana-Farber nurse-scientists receive more than $1.3 million for two research projects

Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

26 May 2020

Increase in out-of-pocket costs associated with lower adherence to neurologic medications

As out-of-pocket costs go up for drugs for the neurologic disorders Alzheimer's disease, peripheral neuropathy and Parkinson's disease, people are less likely to take the drugs as often as their doctors prescribed, according to a study funded by the American Academy of Neurology and published in the February 19, 2020, online issue of Neurology, the medical journal of the American Academy of Neurology.

19 Feb 2020

NUS researchers identify new protein to prevent chemotherapy-induced neuropathy

A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy in cancer patients who receive chemotherapy.

18 Feb 2020

Scientists discover gene mutation involved in paraplegia and epilepsy

Researchers have made an important discovery that could help scientists understand the cause of paraplegia and epilepsy.

1 Nov 2019

USF awarded $2.2 million to study neuromuscular effects of chemotherapy in breast cancer survivors

A University of South Florida College of Nursing researcher has been awarded a $2.2 million grant from the National Institutes of Health's National Cancer Institute to study whether a home-based exercise regimen to help improve gait and balance and strengthen muscles can lessen adverse neuromuscular effects many breast cancer survivors face after chemotherapy.

3 Oct 2019

Raising Awareness of Coeliac Disease with Coeliac UK

An interview with Norma McGough from Coeliac UK, debunking some of the common myths surrounding celiac disease and helping to raise awareness of the condition

12 Sep 2019

LMRI scientists discover cause of debilitating eye disease

Scientists at the Lowy Medical Research Institute have discovered one cause of a progressive, debilitating eye disease called macular telangiectasia type 2 (MacTel).

11 Sep 2019

First genetic cause for a rare eye disease discovered

John A. Moran Eye Center physician-researcher Paul S. Bernstein, MD, PhD, and his patients at the University of Utah played a key role in the recent discovery of the first genetic cause for a rare eye disease.

11 Sep 2019

FDA approves new drug for specific type of highly treatment-resistant tuberculosis

The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis of the lungs.

14 Aug 2019

FDA grants approval for generic versions of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury.

22 Jul 2019